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regimens for hematopoietic stem cell transplantation (HSCT).
Methods: Analysis of all patients who received an allogeneic,
matched-sibling (6/6) HSCT for myeloid malignancies enrolled in
4 different transplant studies between 4/97 and 12/04. These
studies included 3 preparative regimens: (1) IV Busulfan, 130
mg/m2  4 days and Fludarabine, 40 mg/m2  4 days (IVBuFlu);
(2) IV Busulfan, 0.8 mg/kg q6h  4 days and Cyclophosphamide,
60 mg/kg  2 days (IVBuCy), and (3) Fludarabine, 30 mg/m2  4
days and Melphalan, 180 mg/m2 (FM). All patients received the
same GVHD prophylaxis with tacrolimus and minidose metho-
trexate. Results: A total of 176 patients (IVBuFlu 89, IVBuCy
60, and FM  27) were analyzed, and patients’ characteristics are
summarized in Table 1. The median age was signiﬁcantly higher in
the FM group compared to the IVBuFlu and IVBuCy groups.
IVBuFlu had a signiﬁcantly higher proportion of peripheral blood
stem cell transplants (PBSCT) compared with IVBuCy, and more
patients with mixed chimerism on day 30 post transplant compared
with both IVBuCy and FM. The rate of Grade 2-4 acute GVHD
was lowest in the IVBuFlu group (18%), compared with IVBuCy
(34%, P  .01) and FM (26%, P  .2). IVBuFlu continued to have
a signiﬁcantly lower rate of Grade 2-4 acute GVHD among pa-
tients with donor chimerism. Grade 3-4 acute GVHD also favored
the IVBuFlu group (3%) in comparison with IVBuCy (12%, P 
.03) and FM (11%, P .05). The incidence of chronic GVHD was
similar in all regimens. NRM at 1 year was 9% with IVBuFlu, 17%
with IVBuCy (P .2) and 33% with FM (P .002). Conclusions:
The incidence of acute GVHD and NRM differs among myeloa-
blative regimens. These differences are only partially explained by
regimen intensity (Table1).











Median F/U (mo) 63 (38-81) 62 (19-75) 22 (6-50)
Median Age 54 40 47 P < .001 P  .06
MDS/AML 16 (59%) 36 (60%) 89 (100%)
CML 11 (41%) 24 (40%) 0
PBSC 24 (89%) 41 (68%) 76 (85%) P  .5 P  .01
Donor/Mixed
chim 81%/4% 90%/3% 62%/30% P  .05 P < .001
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THE COMPLEX CARE CHALLENGE OF TRANSPLANT PATIENTS AND
FAMILIES: HOW TO EFFECTIVELY PROMOTE CARE ACROSS THE CON-
TINUUM THROUGH ROLE DEVELOPMENT IN THE PROGRAM
Schulte, K.A., Hubner, M., Binari, E., Gaumer, C. Dana-Farber/
Brigham & Women’s Cancer Center, Boston, MA.
Topic: Ambulatory Care Coordination is a synergistic model of
care that provides assistance to transplant (BMT) patients and their
families who are high risk from a clinical and/or ﬁnancial perspec-
tive; eg, second transplant, psychosocial needs, limited ﬁnancial
and or socioeconomic resources, or limited insurance coverage.
Abstract: A multidiscipinary team inclusive of nursing leadership,
administrative leadership, research/program nurses, social workers,
and care coordination nurses had the oppurtunity to assist with the
development and implementation of a new role. This nurse’s role
would be to assist in providing a seamless continuum of patient
care between the ambulatory and inpatient setting, as a well as to
build a bridge to community and home care services. Purpose:
The purpose of this project was to design, develop, and implement
a new nursing role, the Ambulatory BMT RN Care Coordinator.
Our goal was to have this nursing role actively participate in the
pretransplant process. A large focus of the role is to identify
potential discharge issues prior to patient admission by developing
preliminary discharge plans for identiﬁed patients. Interventions:
A multidisciplinary task force met to create a job description and
role. This role was developed from discussion/feedback from in-
patient/oupatient members of nursing staff, social work, ﬁnancial
counselors, and administration. Interpretation:Monthly meetings
have been coordinated between the inpatient and outpatient
groups to evaluate the communication and process on an ongoing
basis. Monthly meetings between the Ambulatory Nurse Leader,
the program/research transplant nurses, the RN Program Manager
for Care Coordination, and the Ambulatory BMT RN Care Co-
ordinator occur in order to continually evaluate the program for its
effectiveness, ease of communication, and its ability to provide
continuous care coordination across both the ambulatory and in-
patient settings. Since inception of this program, 14 months, 225
patients have been identiﬁed and managed by the Ambulatory
BMT RN Care Coordinator. As a result of being exposed to
multiple aspects of the transplant process, this role has served to
identify process and system issues and trends in the industry, eg,
limited pharmacy beneﬁts. Discussion: The ﬁnancial, psychoso-
cial, and clinical needs of this patient population are highly com-
plex and require clear pathways of communication to achieve the
best possible patient outcomes.
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SUCCESSFUL MOBILISATION, HARVEST, AND TRANSPLANT OF STEM
CELLS FOLLOWING AMD3100 IN 3 PAEDIATRIC PATIENTS. THE AUS-
TRALIAN EXPERIENCE
Stephen, K.1, Montgomery, K.1, Bateman, C.1, Calandra, G.2,
Shaw, P.J.1 1. The Children’s Hospital at Westmead, Sydney, NSW,
Australia; 2. AnorMED, Langley, BC, Canada.
We report the successful mobilisation and subsequent transplant
of three patients, using granulocyte cell stimulating factor (GCSF)
and AMD3100, who had failed previous mobilisation attempts.
AMD3100 is a potent and selective antagonist of the CXCR4
chemokine receptor, and blocks binding of its cognate ligand,
encouraging the release of haematopoietic stem cells into the
peripheral circulation. AMD3100 was obtained on a compassionate
basis from AnorMed and given as per protocol, with a pre phase of
10mcg/kg GCSF for 4 days and AMD3100 240mcg/kg given
subcutaneously on day 5, 10-11 hours prior to apheresis and then
given daily until the required number of cells were collected. The
patients diagnoses were Ewings sarcoma, ALL, and Medulloblas-
toma. All were male patients aged between 10-17 years: the 10-
year-old being the youngest patient at the time of administration,
to have received AMD 3100. Each patient had a history of failed
mobilization following a range of regimens and between 1 to 4
attempts at mobilization prior to the commencement of
AMD3100. No side effects of treatment with AMD3100 were
noted. All were successfully collected with adequate PBSCs to
enable reinfusion after either myeloablative chemotherapy or se-
quential tandem high dose therapy (for medulloblastoma). The
Ewing’s sarcoma patient was conditioned with Busulfan/melphalan
and recovered neutrophils of 0.5 109/l after 14 days; he remained
platelet dependent as he progressed soon after BMT. The ALL
patient received total body irradiation 1320 cGy and melphalan
and recovered to neutrophils 	 0.5  109/l after 23 days and
platelets 	 50  109/l after 29 days. The patient with medullo-
blastoma received 4 courses of high dose multiagent therapy with
stem cell rescue and showed prompt haematological recovery after
each course. These three cases illustrate that AMD3100, in com-
bination with GCSF, can achieve successful mobilization and stem
cell collection in previously poorly mobilizing patients. This al-
lowed subsequent delivery of myeloablative chemotherapy fol-
lowed by autologous PBSC infusion and sustained engraftment in
these patients.
458
INCREASING THE SAFETY OF PATIENT-ADMINISTERED OUTPATIENT
CONDITIONING THERAPY WITH ORAL BUSULFAN
Wickline, M.M. 1Seattle Cancer Care Alliance, Seattle, WA.
Patient-administered chemotherapy in the home is without the
controls and safeguards of nurse-administered chemotherapy in
the clinical setting. Oral Busulfan is commonly used as condition-
ing chemotherapy for patients undergoing Hematopoietic Stem
Cell transplantation (HSCT). Because the treatment schedule is
every 6 hours, and patients are usually well enough to remain
outpatient, patients at the Seattle Cancer Care Alliance self-ad-
minister Busulfan at home. Historically, this practice made it dif-
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ﬁcult for the transplant team to have complete assurance that the
patient took every dose correctly and, if patients were admitted to
the inpatient unit prior to completing therapy, to know exactly how
many doses were given and how many remained. The HSCT
Clinical Nurse Specialist led a process improvement effort to
increase the safety of patient-administered oral Busulfan. A new
form was developed, the Busulfan Medication Documentation
Record. Patients and caregivers document Busulfan doses admin-
istered on the form, which becomes a permanent part of the
medical record. Patient Education about Busulfan therapy was
standardized and written resources were updated. A second new
form was developed, the Busulfan Management Flowsheet, which
serves as a record of nursing veriﬁcation of all Busulfan doses.
Outpatient nurses were trained to coach patients on the use of the
Busulfan Medication Documentation Record, and inpatient nurses
were trained to collect the form on admission to the hospital,
which generally occurs the morning after the last dose of Busulfan
is administered at home. If patients are admitted during Busulfan
therapy, nurses know to collect the form to determine how many
doses remain and ensure that no under- or overdosing takes place.
Nurses updated the outpatient and inpatient Busulfan Nursing
Policies and Procedures to reﬂect the system changes. The out-
comes of the process improvement project have been positive.
Nurses have a higher level of conﬁdence that patients understand
the importance of taking Busulfan correctly. On audit, 100% of
Busulfan Medication Documentation Records have been com-
pleted perfectly by patients and caregivers. Additionally, a nurse
discovered a Busulfan dosing error that did not reach the patient
that could have been missed prior to the process improvement.
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TAILORING INITIAL CHEMOTHERAPY EDUCATION TO THE NEEDS OF
HEMATOPOIETIC STEM CELL TRANSPLANT NURSES
Wickline, M.M. University of Washington Medical Center/Seattle Can-
cer Care Alliance, Seattle, WA.
Hematopoietic Stem Cell Transplant (HSCT) nurses need spe-
cialized knowledge in chemotherapy administration. In addition to
the knowledge and skills that all chemotherapy-trained nurses must
possess, the HSCT nurse must have the ability to administer and
manage toxicities for chemotherapy given at extremely high doses
as well as in investigational regimens and for off-label indications.
At the University of Washington Medical Center (Seattle Cancer
Care Alliance), we have developed a Chemotherapy Skills Day that
all nurses who are new to chemotherapy administration attend
after the two-day didactic course, Foundations in Chemotherapy Prac-
tice. The HSCT Clinical Nurse Specialist (CNS), the Oncology
CNS, and the HSCT/Oncology Staff Development Specialist offer
the skills day as a collaborative effort of case-based learning. The
nurses learn in a hands-on, informal environment where they
assimilate new skills using applicable examples from clinical prac-
tice. The HSCT CNS leads the HSCT nurse-learners through
specialized skill acquisition necessary for safe chemotherapy ad-
ministration on the inpatient HSCT units. The HSCT nurses
learn dose veriﬁcation processes, patient teaching standards, safe
handling practices, documentation guidelines and side effect man-
agement unique to the HSCT population for the chemotherapy
agents that they will commonly encounter in their practice. The
skills day is offered twice a year, in conjunction with the 2-day
didactic course. Nurse managers and participants are extremely
satisﬁed with the additional knowledge they gain at the skills day,
and staff nurses on the HSCT and oncology units have noticed an
increased level of skill and conﬁdence in nurses who attend the
Chemotherapy Skills Day than in previous nurses who attended
just the 2-day didactic course.
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A UNIQUE STAFFING STRATEGY
Martin, R.L. Froedtert Hospital, Milwaukee, WI.
A successful BMT requires many elements, including consistent
nursing care. Froedtert Hospital (FH) provides this consistency by
utilizing a unique stafﬁng strategy. Nurses on the BMT unit at FH
work 7/70. Seven seventy requires a nurse to work seven ten hour
shifts in a row and then allows them seven days off. Working seven
days in a row insures consistent nursing care. Seven seventy offers
an extra six hours a day of nursing care to each patient. The overlap
of shifts ensures time to provide extra nursing care, patient educa-
tion, and emotional support. When extra time is not needed for
patient care, the involved nurse may participate in projects to
better the patients’ quality of care. Patients beneﬁt from the con-
tinuity of care 7/70 provides. Caring for a patient seven days in a
row allows the nurse time to get to know the patient. Patients
undergoing a BMT are vulnerable to many complications. Often
the start of these complications is not obvious. A nurse becomes so
familiar with their patients, the initial signs and symptoms of these
complications can be noticed early. With these complications, time
is of the essence and early detection is paramount. FH has tradi-
tionally staffed their units through a centralized nursing ofﬁce.
Unit managers would report unit activity to a stafﬁng ofﬁce that
made the ﬁnal decision. The hospital is currently amidst a pilot to
decentralize stafﬁng. Units were split into clusters and staff nurses
were trained as shift coordinators allowing them to collaborate
within their cluster to make stafﬁng decisions. A decentralized
approach to stafﬁng allows the nursing staff more autonomy. The
BMT unit is clustered with the Hem/Onc unit. The beneﬁts of this
cluster include; similar patients, shared physicians, and geographic
proximity. Physicians have appreciated a decrease in ﬂoat nurses
unfamiliar with the nuances of cancer care. A limited number of
ﬂoat nurses allocated by the nursing ofﬁce continue to be available
when needed. During the 5 months prior to the pilot, the unit
staffed themselves 211 times and during the ﬁrst 5 months of the
pilot, the unit has staffed themselves 372 times. By increasing unit
and cluster availability, the hope is to see a rise in patient and
nursing satisfaction as well as a decrease in errors. FH’s unortho-
dox approach to stafﬁng has provided consistency in patient care
and we are hoping our new cluster model will enhance the quality
of care already provided by the 7/70 model.
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THE DEVELOPMENT OF A PATIENT CLASSIFICATION TOOL ON AN
INPATIENT BLOOD AND MARROW TRANSPLANTATION UNIT
Brandert, M., Cline, D., Johnston, P., Causton, C., Meyers, A. The
University of Texas M. D. Anderson Cancer Center, Houston, TX.
Patient classiﬁcation systems (PCS) have been used as a tool to
determine stafﬁng levels in health care institutions for the past 30
years. The purpose of the PCS was to adequately staff patient care
units without compromising care delivery. In the current health
care arena, an increasing focus on rising health care costs, the
shortage of nurses, and proposals for safer, mandatory stafﬁng
levels have led many hospital administrators and nurse managers to
re-evaluate the standards in their own institutions. The use of
Patient Dependency Systems (PDS) has presented an alternative to
the PCS model. Rather than emphasize solely on the acuity of each
patient, the PDS places a greater focus on the patient’s dependency
on staff to have their needs met. A patient classiﬁcation tool
utilizing the PDS model is currently being developed at our com-
prehensive cancer center. Each inpatient unit is actively involved in
the process of creating a tool speciﬁc to their patient population.
On the inpatient blood and marrow transplant unit, a committee
comprised of nurse management and staff nurses was formed to
evaluate our unit’s needs. From this committee, 9 classiﬁcation
categories have been developed with deﬁned criteria for each. A
point system allocates a set number of points for each criterion in
a particular category. Patients are then placed in a class level (1-5)
based on their total points and reevaluated every shift. The second
part of this model encompasses workload measurement. This pro-
cess will assist in determining the hours of care required by each
patient and quantifying the work done by the nurse during a
particular shift. It will focus on both direct and indirect care
activities, as well as routine activities on the unit. The goals of this
project are:
• Optimal stafﬁng levels for all inpatient units
• Appropriate use and allocation of resources
• Maintaining budget compliance
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